Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in BioCryst Pharmaceuticals, Inc. or BioMarin Pharmaceutical Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how BioCryst Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. compare based on key financial metrics to determine which better meets your investment needs.

About BioCryst Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company’s products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company’s products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Latest Biotechnology and BioCryst Pharmaceuticals, Inc., BioMarin Pharmaceutical Inc. Stock News

As of July 31, 2026, BioCryst Pharmaceuticals, Inc. had a $2.3 billion market capitalization, compared to the Biotechnology median of $252.6 million. BioCryst Pharmaceuticals, Inc.’s stock is up 15.1% in 2026, down 3.9% in the previous five trading days and up 9.25% in the past year.

Currently, BioCryst Pharmaceuticals, Inc. does not have a price-earnings ratio. BioCryst Pharmaceuticals, Inc.’s trailing 12-month revenue is $885.7 million with a -51.7% net profit margin. Year-over-year quarterly sales growth most recently was 7.5%. Analysts expect adjusted earnings to reach $0.660 per share for the current fiscal year. BioCryst Pharmaceuticals, Inc. does not currently pay a dividend.

As of July 31, 2026, BioMarin Pharmaceutical Inc. had a $11.6 billion market cap, putting it in the 79th percentile of all stocks. BioMarin Pharmaceutical Inc.’s stock is up 1% in 2026, up 1.2% in the previous five trading days and up 2.06% in the past year.

Currently, BioMarin Pharmaceutical Inc.’s price-earnings ratio is 43.0. BioMarin Pharmaceutical Inc.’s trailing 12-month revenue is $3.2 billion with a 8.3% net profit margin. Year-over-year quarterly sales growth most recently was 2.8%. Analysts expect adjusted earnings to reach $4.935 per share for the current fiscal year. BioMarin Pharmaceutical Inc. does not currently pay a dividend.

How We Compare BioCryst Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at BioCryst Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

BioCryst Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. Stock Value Grades

Company	Ticker	Value
BioCryst Pharmaceuticals, Inc.	BCRX	B
BioMarin Pharmaceutical Inc.	BMRN	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

BioCryst Pharmaceuticals, Inc. has a Value Score of 62, which is Value. BioMarin Pharmaceutical Inc. has a Value Score of 30, which is Expensive.

The Value Stock Winner: BioCryst Pharmaceuticals, Inc.

As you can clearly see from the Value Grade breakdown above, BioCryst Pharmaceuticals, Inc. is considered to have better value than BioMarin Pharmaceutical Inc.. For investors who focus solely on a company’s valuation, BioCryst Pharmaceuticals, Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

BioCryst Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. Growth Grades

Company	Ticker	Growth
BioCryst Pharmaceuticals, Inc.	BCRX	D
BioMarin Pharmaceutical Inc.	BMRN	A

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

BioCryst Pharmaceuticals, Inc. has a Growth Score of 30, which is Weak. BioMarin Pharmaceutical Inc. has a Growth Score of 83, which is Very Strong.

The Growth Grade Winner: BioMarin Pharmaceutical Inc.

As you can clearly see from the Growth Grade breakdown above, BioMarin Pharmaceutical Inc. has a more attractive growth grade than BioCryst Pharmaceuticals, Inc.. For investors who focus solely on how a company is growing relative to other companies in the same industry, BioMarin Pharmaceutical Inc. could be a good stock to add to their portfolio. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

BioCryst Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.’s Quality Grades

Company	Ticker	Quality
BioCryst Pharmaceuticals, Inc.	BCRX	C
BioMarin Pharmaceutical Inc.	BMRN	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

BioCryst Pharmaceuticals, Inc. has a Quality Score of 47, which is Average. BioMarin Pharmaceutical Inc. has a Quality Score of 56, which is Average.

The Quality Stock Winner: No Clear Winner

Neither BioCryst Pharmaceuticals, Inc. or BioMarin Pharmaceutical Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if BioCryst Pharmaceuticals, Inc. or BioMarin Pharmaceutical Inc. is the better investment when it comes to quality.

Other BioCryst Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. Grades

In addition to Growth, Quality and Value, A+ Investor also provides grades for Momentum and Estimate Revisions.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Earnings estimate revisions scores take into account the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, surprises beget further surprises‐or at least continued sales growth (the exact opposite is generally true, too).

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether BioCryst Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, BioCryst Pharmaceuticals, Inc. or BioMarin Pharmaceutical Inc. Stock?

Overall, BioCryst Pharmaceuticals, Inc. stock has a Value Score of 62, Growth Score of 30 and Quality Score of 47.

BioMarin Pharmaceutical Inc. stock has a Value Score of 30, Growth Score of 83 and Quality Score of 56.

Comparing BioCryst Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.